Literature DB >> 23707408

Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: a new mode of ligand recognition and receptor stabilization.

Amanda Bernardes1, Paulo C T Souza, João R C Muniz, Clarisse G Ricci, Stephen D Ayers, Nili M Parekh, André S Godoy, Daniela B B Trivella, Peter Reinach, Paul Webb, Munir S Skaf, Igor Polikarpov.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of a superfamily of nuclear transcription factors. They are involved in mediating numerous physiological effects in humans, including glucose and lipid metabolism. PPARα ligands effectively treat dyslipidemia and have significant antiinflammatory and anti-atherosclerotic activities. These effects and their ligand-dependent activity make nuclear receptors obvious targets for drug design. Here, we present the structure of the human PPARα in complex with WY14643, a member of fibrate class of drug, and a widely used PPAR activator. The crystal structure of this complex suggests that WY14643 induces activation of PPARα in an unusual bipartite mechanism involving conventional direct helix 12 stabilization and an alternative mode that involves a second ligand in the pocket. We present structural observations, molecular dynamics and activity assays that support the importance of the second site in WY14643 action. The unique binding mode of WY14643 reveals a new pattern of nuclear receptor ligand recognition and suggests a novel basis for ligand design, offering clues for improving the binding affinity and selectivity of ligand. We show that binding of WY14643 to PPARα was associated with antiinflammatory disease in a human corneal cell model, suggesting possible applications for PPARα ligands.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AF-2; DBD; DMEM; DNA-binding domain; Dulbecco's modified Eagle's medium; HCEC; LBD; MD; PBS; PCA; PDB; PPAR; PPARα; Protein Data Bank; RMSF; activation function 2; crystal structure; dry eye disease; human corneal epithelial cells; ligand-binding domain; molecular dynamics; peroxisome proliferator-activated receptor; phosphate-buffered saline; principal component analysis; protein and ligand interaction; root-mean-square fluctuation

Mesh:

Substances:

Year:  2013        PMID: 23707408     DOI: 10.1016/j.jmb.2013.05.010

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  24 in total

1.  Modification of the Orthosteric PPARγ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor.

Authors:  Richard Brust; Hua Lin; Jakob Fuhrmann; Alice Asteian; Theodore M Kamenecka; Douglas J Kojetin
Journal:  ACS Chem Biol       Date:  2017-02-16       Impact factor: 5.100

2.  Long-chain acyl-CoA synthetase 1 interacts with key proteins that activate and direct fatty acids into niche hepatic pathways.

Authors:  Pamela A Young; Can E Senkal; Amanda L Suchanek; Trisha J Grevengoed; Dennis D Lin; Liyang Zhao; Amanda E Crunk; Eric L Klett; Joachim Füllekrug; Lina M Obeid; Rosalind A Coleman
Journal:  J Biol Chem       Date:  2018-09-06       Impact factor: 5.157

3.  Identification of a new hormone-binding site on the surface of thyroid hormone receptor.

Authors:  P C T Souza; A C Puhl; L Martínez; R Aparício; A S Nascimento; A C M Figueira; P Nguyen; P Webb; M S Skaf; I Polikarpov
Journal:  Mol Endocrinol       Date:  2014-02-19

4.  Resveratrol and its metabolites bind to PPARs.

Authors:  E Calleri; G Pochetti; K S S Dossou; A Laghezza; R Montanari; D Capelli; E Prada; F Loiodice; G Massolini; M Bernier; R Moaddel
Journal:  Chembiochem       Date:  2014-05-05       Impact factor: 3.164

5.  Probing the Complex Binding Modes of the PPARγ Partial Agonist 2-Chloro-N-(3-chloro-4-((5-chlorobenzo[d]thiazol-2-yl)thio)phenyl)-4-(trifluoromethyl)benzenesulfonamide (T2384) to Orthosteric and Allosteric Sites with NMR Spectroscopy.

Authors:  Travis S Hughes; Jinsai Shang; Richard Brust; Ian Mitchelle S de Vera; Jakob Fuhrmann; Claudia Ruiz; Michael D Cameron; Theodore M Kamenecka; Douglas J Kojetin
Journal:  J Med Chem       Date:  2016-11-04       Impact factor: 7.446

6.  LCK: a new biomarker candidate for the early diagnosis of acute myocardial infarction.

Authors:  Fei Xu; Xiao Teng; Xin Yuan; Jiakang Sun; Hengchao Wu; Zhe Zheng; Yue Tang; Shengshou Hu
Journal:  Mol Biol Rep       Date:  2014-09-11       Impact factor: 2.316

7.  Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone.

Authors:  Xue-Jiao Wang; Jun Zhang; Shu-Qing Wang; Wei-Ren Xu; Xian-Chao Cheng; Run-Ling Wang
Journal:  Drug Des Devel Ther       Date:  2014-11-07       Impact factor: 4.162

Review 8.  Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis.

Authors:  Virender Kumar; Xiaofei Xin; Jingyi Ma; Chalet Tan; Natalia Osna; Ram I Mahato
Journal:  Adv Drug Deliv Rev       Date:  2021-07-24       Impact factor: 17.873

9.  Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders.

Authors:  Xiaozheng Dou; Dinesh Nath; Henry Shin; Elmar Nurmemmedov; Philip C Bourne; Jian-Xing Ma; Adam S Duerfeldt
Journal:  J Med Chem       Date:  2020-03-10       Impact factor: 8.039

10.  Previous exercise training increases levels of PPAR-α in long-term post-myocardial infarction in rats, which is correlated with better inflammatory response.

Authors:  Marília Harumi Higuchi Santos; Maria de Lourdes Higuchi; Paulo J F Tucci; Shérrira M Garavelo; Márcia M Reis; Ednei L Antonio; Andrey J Serra; Raul Cavalcante Maranhão
Journal:  Clinics (Sao Paulo)       Date:  2016-03       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.